Dianosic
Strasbourg · Founded 2017
About Dianosic
Dianosic was founded in 2017 and develops cutting-edge solutions to resolve patient compliance challenges in Ear, Nose and Throat (ENT) conditions such as chronic allergic rhinitis and chronic sinusitis. Dianosic’s strategic goal is to establish new standards of care in chronic rhinitis and chronic sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This breakthrough formulation is developed with world renowned resorbable polymers experts. This long acting (6 to 12 months), steady releasing, patients and physicians' friendly, has the potential to establish new treatment paradigms. Noteworthy, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.9M
- Last round: Series Unknown (Sep 2025)
- Website: https://dianosic.com/
- Phone: +33144014580
Industries & Categories
Biotechnology, Medical, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/dianosic-109592 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.